Top-Rated StocksTop-RatedNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $58.65 -0.15 (-0.26%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$59.00 +0.35 (+0.60%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Xenon Pharmaceuticals Stock (NASDAQ:XENE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xenon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$58.53▼$60.0050-Day Range$58.65▼$70.9652-Week Range$35.60▼$72.66Volume466,752 shsAverage Volume632,987 shsMarket Capitalization$5.67 billionP/E RatioN/ADividend YieldN/APrice Target$77.13Consensus RatingBuy Company Overview Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its expertise in ion channels, which regulate the electrical activity of nerve cells, to discover and advance potential treatments for conditions with significant unmet medical needs. Xenon’s leading investigational product is azetukalner (XEN1101), an oral, small-molecule potassium-channel opener being studied in epilepsy, including focal-onset seizures, and major depressive disorder. The company also maintains a broader pipeline of drug candidates and research programs directed at neurological conditions, including seizure disorders and other diseases involving abnormal neuronal excitability. Its products remain investigational and are subject to clinical and regulatory review. Founded in 1996, Xenon is headquartered in Vancouver, British Columbia, and conducts research and clinical-development activities in North America and through international clinical studies. The company is led by Chief Executive Officer Ian Mortimer and has developed collaborations with pharmaceutical and biotechnology companies to support the development of selected neuroscience programs.AI Generated. May Contain Errors. Read More Xenon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreXENE MarketRank™: Xenon Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 534th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialXenon Pharmaceuticals has a consensus price target of $77.13, representing about 31.5% upside from its current price of $58.65.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Xenon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($4.73) to ($4.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -12.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -12.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 7.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xenon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.76% of the float of Xenon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 9.09.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 11.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.07 News SentimentXenon Pharmaceuticals has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Xenon Pharmaceuticals this week, compared to 5 articles on an average week.MarketBeat FollowsOnly 1 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,066,447.00 in company stock.Percentage Held by Insiders2.91% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XENE Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Xenon (XENE) and Immix Biopharma (IMMX)September 11 at 8:03 PM | theglobeandmail.comBiohaven plummets, a boon for rival Xenon, on a surprise seizure setbackSeptember 10 at 6:32 PM | msn.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from AnalystsSeptember 8, 2026 | americanbankingnews.comXenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy CareSeptember 4, 2026 | insidermonkey.comXenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy CareSeptember 4, 2026 | finance.yahoo.comInsider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in StockSeptember 2, 2026 | insidertrades.comSteven Gannon Sells 10,000 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) StockAugust 14, 2026 | insidertrades.comSee More Headlines XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $44.82 at the beginning of the year. Since then, XENE stock has increased by 30.9% and is now trading at $58.65. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.05. Read the conference call transcript. When did Xenon Pharmaceuticals IPO? Xenon Pharmaceuticals (XENE) raised $44 million in an initial public offering on Friday, October 17th 2014. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' top institutional investors include BlackRock Inc. (7.78%), California State Teachers Retirement System (5.79%), Jupiter Topco LLC (4.33%) and Wellington Management Group LLP (1.47%). Insiders that own company stock include Gary Patou, Ian Mortimer, Sherrington Robin, Andrea Difabio, Steven Gannon, Gillian Cannon, Christopher John Kenney and Sherry Aulin. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/06/2026Today9/12/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XENE's financial health is in the Green zone, according to TradeSmith. XENE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XENE CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees370Year Founded1996Price Target and Rating Average Price Target for Xenon Pharmaceuticals$77.13 High Price Target$100.00 Low Price Target$55.00 Potential Upside/Downside+31.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$345.91 million Net MarginsN/A Pretax Margin-4,598.59% Return on Equity-43.98% Return on Assets-41.72% Debt Debt-to-Equity RatioN/A Current Ratio21.01 Quick Ratio21.02 Sales & Book Value Annual Sales$7.50 million Price / Sales755.96 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book7.79Miscellaneous Outstanding Shares96,670,000Free Float93,853,000Market Cap$5.67 billion OptionableOptionable Beta0.61 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:XENE) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XENE Stock Alerts